Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/304% below fair value
$29.94−0.54 (-1.76%)
Close on Nov 13, 2026Market cap $1.54BP/E –Yield 0.00%
Immunocore enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Immunocore's enterprise value was $749.14M on Nov 11, 2026, against $1.10B a year earlier. Over the last 5 years it ranged from -$315.07M to $3.07B, with a median of $769.02M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $749.14M | -12.8% |
| 2025 | Dec 31, 2025 | $859.39M | +49.6% |
| 2024 | Dec 31, 2024 | $574.47M | -80.1% |
| 2023 | Dec 29, 2023 | $2.88B | – |
| 2022 | Dec 30, 2022 | -$308.97M | – |
See a number that looks wrong?